Tag: Iambic Therapeutics

Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs

Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs

Series B now exceeds $150 million following Investment from Mubadala Capital, Exor Ventures and QIA, Alongside Additional Funding by Existing Investors June 18, 2024 05:00 AM Pacific Daylight Time SAN DIEGO–(BUSINESS WIRE)–Iambic Therapeutics, a clinical-stage…

Read More Read More

Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $37,999,999.00 in New Equity Investment.

Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $37,999,999.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Iambic Therapeutics is raising up to $37,999,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Miller played a…

Read More Read More

Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $109,999,999.00 in New Equity Investment.

Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $109,999,999.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Iambic Therapeutics is raising $109,999,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Miller played a key role…

Read More Read More